Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 57Neoplasms 11Lung Neoplasms 11Small Cell Lung Carcinoma 8Thyroid Neoplasms 7Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma 6Breast Neoplasms 6Adenocarcinoma 6Colorectal Neoplasms 5Colonic Neoplasms 5Thyroid Diseases 4Thyroid Cancer, Papillary 4Thoracic Neoplasms 4Sarcoma 4Respiratory Tract Neoplasms 4Respiratory Tract Diseases 4Pancreatic Neoplasms 4Neuroendocrine Tumors 4Neoplasms by Site 4Melanoma 4Lung Diseases 4Endometrial Neoplasms 4Endocrine System Diseases 4Endocrine Gland Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Bronchogenic 4Bronchial Neoplasms 4Uterine Cervical Neoplasms 3

Interventions

sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Glioblastoma × Thoracic × Clear all
NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡